Fredun Pharmaceuticals Share Price Today | Stock Price & Fredun Pharmaceuticals Share Screener
As of October 5, 2026, the live Fredun Pharmaceuticals share price (NSE: FREDUN) is ₹1,363.20 on NSE and ₹1,366.65 on BSE, up 0.59% from the previous close, with shares trading between ₹1,322.10 and ₹1,398.00 in today's trading session, and a 52-week range of ₹1,221.60–₹1,505.80. Check FREDUN 52-week high low for the annual price range and momentum. Use the Fredun Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Fredun Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹228 and net income of ₹13, with EBITDA of ₹32, an operating margin of 14.0% and a profit margin of 5.7%.
Fredun Pharmaceuticals Share Price Chart
Track the current stock price of Fredun Pharmaceuticals with an interactive chart. Analyse FREDUN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Fredun Pharmaceuticals stock quote in one place.
The quote of ₹1,363.20 sits between the 52-week low of ₹1,221.60 and the 52-week high of ₹1,505.80, and the latest session moved 0.59% from the previous close.
Fredun Pharmaceuticals Company Profile - Fundamental Screener
Screen Fredun Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for FREDUN shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE194R01017.
Company Details
Classification
Identifiers and Leadership
Fredun Pharmaceuticals Balance Sheet Screener
Screen FREDUN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹642, up from ₹487 in 2025.
Latest statistics put total assets at ₹642 and shareholder funds at ₹278, with a leverage ratio of 0.93.
| Item | 2026 | 2025 |
|---|---|---|
Assets |
||
| Total Assets | 642 | 487 |
| Current Assets | 498 | 427 |
| Fixed Assets | 118 | 53 |
Liabilities |
||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 67 | 18 |
| Non-Current Liabilities | 0 | 0 |
Shareholders' Equity |
||
| Total Equity | 278 | 141 |
| Share Capital | 6 | 5 |
| Reserves & Surplus | 259 | 137 |
Fredun Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Fredun Pharmaceuticals income statement and profit fundamentals. Analyze FREDUN quarterly results. Fredun Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹228 and net profit was ₹13, equal to earnings per unit of ₹23.82, at an operating margin of 14%.
In that period expenses were ₹196, interest cost ₹9 and tax ₹7. The next period listed, 2026-Mar, shows revenue of ₹210 and net profit of ₹11.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 228 | 210 | 160 | 144 | 119 | 165 | 286 | 0 | 0 |
| Expenses | 196 | 184 | 135 | 123 | 103 | 150 | 251 | 0 | 0 |
Operating Costs and Margins | |||||||||
| EBITDA | 32 | 26 | 25 | 21 | 17 | 15 | 35 | 0 | 0 |
| Operating Profit % | 14.00% | 12.00% | 16.00% | 14.00% | 14.00% | 9.00% | 12.00% | 0.00% | 0.00% |
| Depreciation | 4 | 3 | 2 | 2 | 1 | 2 | 3 | 0 | 0 |
| Interest | 9 | 15 | 11 | 8 | 7 | 8 | 14 | 0 | 0 |
Profit and Earnings | |||||||||
| Profit Before Tax | 21 | 11 | 14 | 13 | 9 | 7 | 20 | 0 | 0 |
| Tax | 7 | 1 | 4 | 3 | 2 | 1 | 7 | 0 | 0 |
| Net Profit | 13 | 11 | 11 | 9 | 7 | 6 | 14 | 0 | 0 |
| EPS | 23.82 | 19.70 | 22.19 | 19.98 | 14.33 | 12.71 | 29.09 | 0.00 | 0.00 |
Fredun Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen FREDUN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹12, and net cash flow was an inflow of ₹60.
Over the same period, investing activities used ₹74 and financing activities provided ₹121.
| Item | 2026-March | 2025-March |
|---|---|---|
Cash from Operations and Investing | ||
| Operating Activities | 12 | -17 |
| Investing Activities | -74 | -6 |
Financing and Net Cash | ||
| Financing Activities | 121 | 27 |
| Net Cash Flow | 60 | 4 |
Fredun Pharmaceuticals Shareholding Pattern Screener
See Fredun Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Fredun Pharmaceuticals promoter holding and ownership changes for FREDUN on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jul, promoters held 44.57%, foreign institutions 1.06%, domestic institutions 2.94% and the public 43.62%, spread across 9,598 shareholders.
The shareholder count was 9,598 in 2026-Jul, compared with 8,903 in 2026-Jun.
| Item | 2026-Jul | 2026-Jun | 2026-Mar | 2026-Feb | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 44.57% | 44.57% | 44.17% | 43.06% | 43.06% | 48.93% | 48.93% | 48.93% |
Institutional Investors | ||||||||
| FII Holding | 1.06% | 1.06% | 1.06% | 1.06% | 0.46% | 0.01% | 0.00% | 0.00% |
| DII Holding | 2.94% | 2.94% | 2.83% | 2.89% | 3.48% | 1.60% | 1.59% | 1.59% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.62% | 43.79% | 44.66% | 45.63% | 45.18% | 43.74% | 44.52% | 44.50% |
| Other Holding | 7.81% | 7.65% | 7.28% | 7.37% | 7.83% | 5.72% | 4.96% | 4.98% |
| Shareholder Count | 9,598 | 8,903 | 8,400 | 8,443 | 8,749 | 8,120 | 7,906 | 7,976 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Fredun Pharmaceuticals. Fredun Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.70 per unit for 2026-March, a yield of 0.05%, compared with ₹0.70 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.70, ₹0.70 and ₹0.70 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.70 | 0.05% |
| 2025-March | ₹0.70 | 0.13% |
| 2024-March | ₹0.70 | 0.31% |
| 2023-March | ₹0.70 | 0.29% |
| 2022-March | ₹0.70 | 0.27% |
| 2021-March | ₹0.70 | 0.23% |
| 2020-March | ₹0.66 | 0.43% |
| 2019-March | ₹0.65 | 1.67% |
| 2018-March | ₹1.00 | 0.71% |
| 2017-March | ₹0.60 | 1.26% |
Fredun Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include Fredun Pharmaceuticals stock. Check FREDUN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Fredun Pharmaceuticals Market Events Screener - Corporate Actions
Get Fredun Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Fredun Pharmaceuticals stock events that may affect FREDUN share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 5, 2026, with a record date of August 5, 2026.
It is followed by Bonus dated July 16, 2026 and Annual General Meeting dated June 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-05 | 2026-08-05 | Quarterly Result Announcement | NA | 22.33% |
| 2026-07-16 | 2026-07-16 | Bonus | 2:1 | 7.27% |
| 2026-06-30 | 2026-06-30 | Annual General Meeting | NA | 18.48% |
| 2026-06-23 | 2026-06-23 | Dividend | ₹ 0.70 /share | 1.92% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | 5.79% |
| 2026-02-16 | 2026-02-16 | Extraordinary General Meeting | NA | 21.57% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 10.64% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | -9.98% |
| 2025-10-22 | 2025-10-22 | Extraordinary General Meeting | NA | 27.12% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | 8.06% |
| 2025-09-23 | 2025-09-23 | Dividend | ₹ 0.70 /share | 57.68% |
| 2025-07-30 | 2025-07-30 | Quarterly Result Announcement | NA | 11.44% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 6.41% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 3.02% |
| 2024-10-26 | 2024-10-26 | Quarterly Result Announcement | NA | -6.18% |
Fredun Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen FREDUN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,430 | 36.44 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 251,877 | 86.51 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 185,125 | 85.91 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 121,966 | 26.32 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 112,032 | 33.44 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 108,247 | 99.70 | 6,868 | 22.01% | 890 | 64.04 |
| Dr Reddys Laboratories | 103,983 | 32.05 | 35,059 | 3.90% | 4,158 | 63.11 |
| Mankind Pharma | 103,968 | 48.73 | 14,636 | 14.85% | 1,938 | 55.24 |
| Aurobindo Pharma | 98,004 | 26.36 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 95,091 | 16.99 | 29,039 | 26.75% | 5,356 | 35.30 |
Fredun Pharmaceuticals Company Announcements - News & Reports Screener
Screen FREDUN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated September 30, 2026 and September 30, 2026.
| Date | Update | Actions |
|---|---|---|
| Closure of Trading Window | - | |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-09-30 | Revised Outcome Of Board Meeting Dated 16Th September 2026 | - |
| 2026-09-29 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-16 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-09-16 | Board Meeting Outcome for Allotment Of 271200 Equity Shares To Non-Promoter Upon Conversion Of Warrants Into Equity Shares | - |
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) | - |
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-08 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-17 | Intimation Regarding Permission To Trade And Admission Of Equity Shares To Dealings On The National Stock Exchange Of India Limited. | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-14 | Statement Of Deviation Or Variation For The Quarter Ended June 30 2026 | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-05 | Outcome Of The Board Meeting | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,363.20, within a 52-week range of ₹1,221.60 to ₹1,505.80. The P/E ratio is 52.37 and the P/B ratio is 8.53, with earnings per unit of ₹66.81. Market capitalisation stands at ₹2,340.14 Cr and the dividend yield is 0.02%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 2 balance sheet periods, 9 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.